[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351620-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351620-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multi-omics-analysis-and-functional-validation-reveal-the-oncogenic-role-of-trip13","Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13","","Multi-omics analysis and functional validation investigate how Thyroid hormone receptor-interacting protein 13 (TRIP13) influences cancer immune infiltration and pan-cancer outcomes. Pan-cancer datasets from public resources are systematically analyzed to map TRIP13 expression, prognostic associations, and pathway involvement, including immune regulators, immune-cell infiltration, TMB, and MSI, alongside single-cell expression patterns. In vitro experiments test functional effects, identifying an E2F1-driven TRIP13–HECTD3 axis that promotes tumor progression and palbociclib resistance in prostate cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multi-omics-analysis-and-functional-validation-reveal-the-oncogenic-role-of-trip13/351620/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multi-omics-analysis-and-functional-validation-reveal-the-oncogenic-role-of-trip13/351620.png","ImageObject",300,407,{"name":42,"@type":43},"Chumphorn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main biological focus of the study on TRIP13?","Question",{"text":63,"@type":64},"The study centers on how TRIP13, an AAA-ATPase family enzyme, affects cancer progression and its links to immune modulation and prognosis across multiple cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were pan-cancer data and immune-related associations evaluated?",{"text":68,"@type":64},"Public multi-omics resources were used to assess TRIP13 expression across cancer types and correlate it with prognosis, immune regulators, tumor immune-cell infiltration, and metrics including TMB and MSI.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism is proposed to explain TRIP13’s pro-tumor effect in prostate cancer?",{"text":72,"@type":64},"E2F1 transcriptionally activates TRIP13, which then drives downstream upregulation of the ubiquitin ligase HECTD3, shaping tumor progression and therapy-related sensitivity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351620,1790942138,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","TYPE Original Research PUBLISHED 22 April 2026  \nDOI 10.3389/fimmu.2026.1691436  \nOPEN ACCESS  \nEDITED BY  \nParmanand Malvi,  \nUniversity of Alabama at Birmingham, United States  \nREVIEWED BY  \nPeng Liu,  \nSun Yat-sen University Cancer Center (SYSUCC), China  \nWangli Mei,  \nTongji University, China  \n*CORRESPONDENCE  \nYinhuai Wang  \n[wangyinhuai@csu.edu.cn](wangyinhuai@csu.edu.cn)[ ](wangyinhuai@csu.edu.cn)Jing Li  \n [lijing2017@csu.edu.cn](lijing2017@csu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 23 August 2025  \nREVISED 18 February 2026  \nACCEPTED 18 February 2026  \nPUBLISHED 22 April 2026  \nCITATION  \nZhao Y, Zhao Y, Liu R, Li J and Wang Y (2026) Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13 .  \nFront. Immunol. 17:1691436 .  \ndoi: 10.3389/fimmu.2026.1691436  \nCOPYRIGHT  \n© 2026 Zhao, Zhao, Liu, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMulti-omics analysis and functional validation reveal the oncogenic role of TRIP13  \nYuanqiao Zhao 1†, Yongqi Zhao 1†, Ruilin Liu 1, Jing Li 2* and Yinhuai Wang 1*  \n1 Department of Urology, The Second Xiangya Hospital, Central South University, Changsha,  \nHunan, China, 2 Department of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China  \nBackground: Thyroid hormone receptor-interacting protein 13 (TRIP13), an enzyme from the AAA-ATPase family, facilitates the assembly or disassembly of protein complexes and participates in various biological processes. However, its impact on cancer immune inﬁltration and pan-cancer prognosis remains largely unexplored.  \nMethods: Pan-cancer multi-omics data from publicly available resources were systematically analyzed to evaluate TRIP13 expression across various cancer types and its association with patient prognosis. In addition, functional enrichment analyses were conducted to investigate TRIP13-related biological processes and pathways. The analysis included GSEA enrichment, correlation with immune regulator expression, tumor immune cell inﬁltration, association with tumor mutational burden (TMB), and correlation with microsatellite instability (MSI) . Additionally, single-cell data were used to explore the expression and potential role of TRIP13 at the single-cell level. We subsequently conducted a series of in vitro experiments.  \nResults: Our comprehensive pan-cancer analysis reveals signiﬁcantly elevated TRIP13 expression across multiple cancer types and links it to poor prognostic outcomes. TRIP13 primarily activates pathways such as ubiquitination, cell cycle regulation, and DNA repair to drive tumor progression. Additionally, TRIP13 expression exhibits complex associations with various immune regulators and immune cells. In prostate cancer, TRIP13 shows marked overexpression and is associated with unfavorable prognosis. We identiﬁed a signiﬁcant upregulation of TRIP13 in proliferative tumor stem-like populations in prostate cancer . Consistently, prostate cancer cells that acquired resistance to CDK4/6 inhibitors displayed marked TRIP13 overexpression, and functional assays revealed that TRIP13 modulates cellular sensitivity to these agents . Mechanistically, we demonstrated that E2F1 transcriptionally activates TRIP13, which in turn drives the upregulation of the downstream ubiquitin ligase HECTD3 .  \nConclusion: This study reveals aberrant TRIP13 expression across multiple cancers and its association with immune modulation and tumor aggressiveness. The elevation of TRIP13 in palbociclib resistant prostate cancer, togeth","cbCaihvyBcE62EBe","https://ap.wps.com/l/cbCaihvyBcE62EBe","pdf",14098285,"English","# Introduction\n# Methods\n## Pan-cancer multi-omics analysis\n## Single-cell analysis\n## In vitro experiments\n# Results\n## TRIP13 expression and pan-cancer prognosis\n## Immune regulation associations\n## Prostate cancer validation and drug resistance\n## Mechanistic E2F1–TRIP13–HECTD3 axis\n# Conclusion","[{\"question\":\"What is the main biological focus of the study on TRIP13?\",\"answer\":\"The study centers on how TRIP13, an AAA-ATPase family enzyme, affects cancer progression and its links to immune modulation and prognosis across multiple cancers.\"},{\"question\":\"How were pan-cancer data and immune-related associations evaluated?\",\"answer\":\"Public multi-omics resources were used to assess TRIP13 expression across cancer types and correlate it with prognosis, immune regulators, tumor immune-cell infiltration, and metrics including TMB and MSI.\"},{\"question\":\"What mechanism is proposed to explain TRIP13’s pro-tumor effect in prostate cancer?\",\"answer\":\"E2F1 transcriptionally activates TRIP13, which then drives downstream upregulation of the ubiquitin ligase HECTD3, shaping tumor progression and therapy-related sensitivity.\"}]","Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13 | PDF",1790094973,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6ec687c1db0d3f9575225577892b574.webp",983,1389,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bebb5949a2d518d557c197fa7606cde.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de30f20fc97d624595f41531828b57df.webp",981,1386,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efb65ac928cb95e2a536ff0271e08c2f.webp",980,1385]